GT201000080A - Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
GT201000080A
GT201000080A GT201000080A GT201000080A GT201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A GT 201000080 A GT201000080 A GT 201000080A
Authority
GT
Guatemala
Prior art keywords
benzimidazol
crystal form
carboxamida
pirrolidin
methyl
Prior art date
Application number
GT201000080A
Other languages
English (en)
Spanish (es)
Inventor
Lawrence Kolaczkowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000080A publication Critical patent/GT201000080A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GT201000080A 2007-10-12 2010-04-09 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida GT201000080A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
GT201000080A true GT201000080A (es) 2012-04-03

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000080A GT201000080A (es) 2007-10-12 2010-04-09 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (28)

Country Link
US (4) US8372987B2 (https=)
EP (2) EP2212327A1 (https=)
JP (4) JP2011500589A (https=)
KR (2) KR20100090769A (https=)
CN (2) CN101821270A (https=)
AU (1) AU2008310781B2 (https=)
BR (1) BRPI0816221A8 (https=)
CA (2) CA3006332A1 (https=)
CO (1) CO6280493A2 (https=)
CR (1) CR11368A (https=)
DK (1) DK2722046T3 (https=)
DO (1) DOP2010000099A (https=)
EC (1) ECSP10010150A (https=)
ES (1) ES2620299T3 (https=)
GT (1) GT201000080A (https=)
MX (1) MX350019B (https=)
MY (1) MY156691A (https=)
NZ (1) NZ583209A (https=)
PA (1) PA8798401A1 (https=)
PH (1) PH12012501636A1 (https=)
PL (1) PL2722046T3 (https=)
PT (1) PT2722046T (https=)
RU (2) RU2476434C2 (https=)
SG (1) SG185297A1 (https=)
TW (1) TWI422588B (https=)
UA (2) UA113277C2 (https=)
WO (1) WO2009049111A1 (https=)
ZA (1) ZA201002090B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) * 2016-03-09 2019-03-28 Crystal Pharmatech Co., Ltd. Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) * 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2

Also Published As

Publication number Publication date
BRPI0816221A8 (pt) 2015-09-22
EP2212327A1 (en) 2010-08-04
JP2019001811A (ja) 2019-01-10
CA3006332A1 (en) 2009-04-16
CN101821270A (zh) 2010-09-01
US20140024838A1 (en) 2014-01-23
RU2010116397A (ru) 2011-11-20
NZ583209A (en) 2012-06-29
MX2010003772A (es) 2010-04-21
CN105367554A (zh) 2016-03-02
ECSP10010150A (es) 2010-06-29
JP2011500589A (ja) 2011-01-06
SG185297A1 (en) 2012-11-29
EP2722046B1 (en) 2016-12-21
RU2012147692A (ru) 2014-05-20
PL2722046T3 (pl) 2017-06-30
US20130123317A1 (en) 2013-05-16
US9580410B2 (en) 2017-02-28
US8372987B2 (en) 2013-02-12
ZA201002090B (en) 2011-11-30
PT2722046T (pt) 2017-03-15
WO2009049111A1 (en) 2009-04-16
US8835647B2 (en) 2014-09-16
US20150148392A1 (en) 2015-05-28
CA2696424C (en) 2018-07-10
CA2696424A1 (en) 2009-04-16
AU2008310781A1 (en) 2009-04-16
RU2476434C2 (ru) 2013-02-27
UA113277C2 (xx) 2017-01-10
CO6280493A2 (es) 2011-05-20
JP2017071618A (ja) 2017-04-13
MY156691A (en) 2016-03-15
DOP2010000099A (es) 2017-04-30
JP2014237659A (ja) 2014-12-18
UA101961C2 (xx) 2013-05-27
US20090099245A1 (en) 2009-04-16
BRPI0816221A2 (pt) 2015-06-16
TW200932747A (en) 2009-08-01
KR20100090769A (ko) 2010-08-17
EP2722046A1 (en) 2014-04-23
AU2008310781B2 (en) 2013-03-28
KR20160039312A (ko) 2016-04-08
MX350019B (es) 2016-12-09
CR11368A (es) 2010-10-25
PA8798401A1 (es) 2009-05-15
PH12012501636A1 (en) 2015-07-10
ES2620299T3 (es) 2017-06-28
TWI422588B (zh) 2014-01-11
DK2722046T3 (en) 2017-03-20

Similar Documents

Publication Publication Date Title
GT201000080A (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
CU20110052A7 (es) Compuestos orgánicos
UY32730A (es) Inhibidores de cyp17
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
NI201200023A (es) Derivados de 5-fluoropirimidinona
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CR11871A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3- dioxigenasa
PA8809001A1 (es) Compuestos organicos
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
MA32938B1 (fr) Composes organiques
MX2011007763A (es) Metodos y composiciones para tratamiento de cancer de pulmon.
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
ECSP099818A (es) Procesos para la preparacion de pirazoles
ECSP15032859A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboxilato
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
CO6341625A2 (es) Derivados de indol como agentes anticáncer
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
EA201270253A1 (ru) Производные n1-ацил-5-фторпиримидинона